The 20 most recent market catalysts affecting $NVAX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 12, 2026
Corporate Catalyst
Bearish
Impact 75
Analysts Revise Financial Forecasts for Novavax
Analysts covering Novavax have revised their financial forecasts downward for 2027, cutting revenue projections from US$282 million to US$246 million and increasing loss per share …
Nov 8, 2026
Corporate Catalyst
Bullish
Impact 55
B. Riley Adjusts Price Target on Novavax to $16
B. Riley's decision to lower Novavax's price target from $18 to $16, despite maintaining a 'Buy' rating, indicates a nuanced view of the company's future. This adjustment likely st…
Oct 29, 2026
Corporate Catalyst
Bullish
Impact 55
TD Cowen Raises Novavax Price Target to $11
TD Cowen, an analyst firm, has raised its price target for Novavax (NVAX) from $9 to $11. This change reflects an updated, more favorable outlook on Novavax's equity from the firm.…
Oct 19, 2026
Corporate Catalyst
Neutral
Impact 75
Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push
Shah Capital, Novavax's second-largest shareholder, sold a significant portion of its stake and is stepping back from activist investing, converting its Schedule 13D filing to a pa…
Oct 15, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Sell on Novavax, Raises Price Target to $8
Citigroup's analyst Geoff Meacham maintained a 'Sell' rating on Novavax, indicating a continued negative outlook on the company's prospects. However, the price target was raised fr…
Oct 7, 2026
Corporate Catalyst
Neutral
Impact 75
Transcript: Novavax Q2 2026 Earnings Conference Call
This 8-K filing is a transcript of Novavax's Q2 2026 earnings call, detailing the company's financial results and operational highlights. The key takeaway is the significant progre…
Oct 6, 2026
Geopolitical Risk
Bearish
Impact 65
Novavax shares are trading lower, possibly as the stocks sells of from recent strength related to a suspected pneumonic plague in Russia.
The headline points to Novavax's stock experiencing a sell-off, likely due to profit-taking after a speculative rally. This rally was triggered by unconfirmed reports of a pneumoni…
Oct 6, 2026
Market Technicals
Bearish
Impact 55
Novavax Stock Falls Back: What's Going On?
Novavax shares experienced a sharp, speculative rally on Monday following reports of a suspected pneumonic plague case in Russia. This filing indicates that the stock is now retrea…
Oct 5, 2026
Geopolitical Risk
Bullish
Impact 75
Novavax Shorts on Edge as Russia Plague Fears Spread
A suspected plague death at a Russian research institute, though unconfirmed and potentially misdiagnosed as pneumonia, sparked a 'fear trade' reminiscent of early pandemic days. T…
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 65
Novavax Stock Rises Despite No Confirmed News Behind the Matrix-M Rumor
Novavax (NVAX) stock is experiencing a rise, primarily attributed to an unconfirmed rumor circulating among retail traders regarding its Matrix-M adjuvant. The rumor suggests a fav…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 75
Novavax shares are trading higher. Strength may be due to an increase in investor attention related to an unconfirmed rumor suggesting that Matrix-M has a favorable safety profile with mostly mild-to-moderate, self-limiting side effects.
This headline indicates a significant positive catalyst for Novavax, driven by an unconfirmed rumor about its Matrix-M adjuvant's safety profile. If true, a favorable safety profil…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 75
Watching Novavax; Shares Trading Higher In The Session, Traders Circulate Unconfirmed Rumor Suggesting Clinical Data Show That Matrix-M Has A Favorable Safety Profile With Mostly Mild-To-Moderate, Self-Limiting Side Effects
The unconfirmed rumor regarding Novavax's Matrix-M adjuvant having a favorable safety profile is a significant corporate catalyst. Positive clinical data, especially concerning saf…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 85
Novavax Stock Climbs Monday: What's Going On?
Novavax received regulatory approvals from the U.S. FDA, EU, and Japan for its updated COVID-19 vaccine, Nuvaxovid, ahead of the 2026-2027 autumn vaccination campaign. This validat…
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 65
Novavax's Partners Receive Approvals For Nuvaxovid Formulation To Target SARS-CoV-2 XFG Variant
Novavax's partners have successfully obtained approvals for the Nuvaxovid formulation targeting the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets inc…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 75
Novavax Stock Rallies Tuesday: What's Happening?
Novavax (NVAX) is experiencing a significant rally driven by a confluence of factors. Firstly, broader positive sentiment in the vaccine and mRNA sector, sparked by Moderna and Mer…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 65
Novavax Stock Moves Higher Wednesday: What's Driving the Action?
Novavax's stock is rising not due to its own direct news, but as a beneficiary of a significant clinical breakthrough by Merck and Moderna in the oncology space. Their successful P…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Novavax Raises FY2026 Sales Guidance from $230.000M-$270.000M to $235.000M-$275.000M vs $389.234M Est
Novavax has updated its financial outlook for FY2026, increasing its sales guidance from $230M-$270M to $235M-$275M. While an upward revision typically signals positive momentum, t…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Novavax Q2 EPS $(0.32) Beats $(0.37) Estimate, Sales $56.698M Beat $52.513M Estimate
This headline represents a positive corporate catalyst for Novavax. Beating both EPS and sales estimates suggests that the company is performing better than analysts anticipated, w…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.